A New Predictor of the Likelihood of Breast Cancer Recurrence

Oncotype DX Genomic Assay is a sophisticated genetic test that allows oncologists to predict the likelihood of early-stage breast cancer recurrence within 10 years. Rocky Mountain Cancer Centers’ physician Dev Paul and an RMCC patient explained their experiences with the test during 7News’ 5 p.m. broadcast on Wednesday, September 14.